14 terminated, 6 recruiting, 5 active not recruiting, 5 completed. 19 Phase 1, 16 Phase 2, 2 Phase 3.
Follow ADC Therapeutics S.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) Loncastuximab tesirine, Rituximab or rituximab biosimilar - Post-transplant Lymphoproliferative Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Utah | 23 | 2026-11-01 | 2026-10-09 |
| Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma Epcoritamab, Loncastuximab Tesirine - Large B-cell Lymphoma, Relapse | Phase 2 | Recruiting | University of Miami | 26 | 2026-01-07 | 2026-10-15 |
| Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL) Loncastuximab Tesirine, Rituximab - Relapsed or Refractory Large B-cell Lymphoma | Phase 2 | Recruiting | University of Utah | 29 | 2025-08-25 | 2026-10-16 |
| Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR) Loncastuximab tesirine and rituximab (Lonca-R) - Central Nervous System Lymphoma | Phase 1 | Recruiting | University of Utah | 12 | 2025-03-18 | 2026-08-10 |
| A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Odronextamab, Loncastuximab tesirine, Rituximab - B-cell Non Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | University of Birmingham | 210 | 2024-05-02 | 2026-02-20 |
| Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia Loncastuximab Tesirine and Acalabrutinib - Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | University of Alabama at Birmingham | 24 | 2023-12-18 | 2026-10-20 |
| A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) Loncastuximab Tesirine - Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Terminated | ADC Therapeutics S.A. | 5 | 2023-07-28 | 2026-07-20 |
| Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma Cyclophosphamide, Doxorubicin, Etoposide - Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Phase 2 | Active not recruiting | University of California, Davis | 24 | 2023-05-24 | 2026-09-28 |
| A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors ADCT-601, Gemcitabine - Advanced Solid Tumors | Phase 1 | Terminated | ADC Therapeutics S.A. | 128 | 2022-07-13 | 2025-05-22 |
| Long-term Registry of Patients Treated With Loncastuximab Tesirine B-Cell Lymphomas | Withdrawn | ADC Therapeutics S.A. | 2022-06-30 | 2022-06-22 | ||
| A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) Loncastuximab Tesirine, Rituximab - Diffuse Large B-cell Lymphoma | Phase 2 | Terminated | ADC Therapeutics S.A. | 41 | 2022-06-21 | 2025-01-30 |
| Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg - Marginal Zone Lymphoma | Phase 2 | Recruiting | University of Miami | 50 | 2022-06-21 | 2026-09-21 |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) Loncastuximab Tesirine, Polatuzumab Vedotin, Glofitamab - B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | ADC Therapeutics S.A. | 154 | 2022-06-17 | 2026-07-17 |
| Loncastuximab Tesirine in WM Loncastuximab Tesirine, Dexamethasone - Waldenstrom Macroglobulinemia | Phase 2 | Active not recruiting | Shayna Sarosiek, MD | 21 | 2022-02-17 | 2026-05-20 |
| Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma Loncastuximab tesirine, Rituximab - Follicular Lymphoma | Phase 2 | Recruiting | Juan P. Alderuccio, MD | 100 | 2022-02-11 | 2026-03-23 |
| A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) Loncastuximab tesirine, Prednisone, Rituximab - Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | ADC Therapeutics S.A. | 2022-02-01 | 2022-03-29 | |
| ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN ADCT-301 - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 2 | Terminated | Gwynn Long, M.D. | 3 | 2021-12-07 | 2026-05-01 |
| Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma Loncastuximab Tesirine, Idelalisib - Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 2 | Terminated | ADC Therapeutics S.A. | 6 | 2021-11-04 | 2023-10-23 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors ADCT-901 - Advanced Solid Tumors | Phase 1 | Completed | ADC Therapeutics S.A. | 30 | 2021-09-09 | 2025-05-22 |
| Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Loncastuximab Tesirine, Rituximab, Gemcitabine - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | ADC Therapeutics S.A. | 440 | 2020-09-16 | 2026-04-28 |
Showing 20 of 34. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (10) · Lymphoma (8) · Lymphoma, Follicular (5) · Lymphoma, Non-Hodgkin (5) · Recurrence (5) · Lymphoma, Mantle-Cell (4) · Lymphoma, B-Cell (3) · Burkitt Lymphoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Hodgkin Disease (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, B-Cell, Marginal Zone (2) · Pancreatic Neoplasms (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)
loncastuximab tesirine (22) · Rituximab (9) · Cyclophosphamide (2) · Dexamethasone (2) · Doxorubicin (2) · Etoposide (2) · Gemcitabine (2) · Prednisone (2) · Vincristine (2) · CT-P10 (1) · Calcium Dobesilate (1) · Calmodulin (1) · Carboplatin (1) · Ifosfamide (1) · Immunotherapy, Adoptive (1)
United States (32) · United Kingdom (12) · Spain (10) · Italy (9) · Belgium (8) · France (6) · Czechia (4) · Hungary (3) · Poland (3) · Switzerland (3) · Australia (2) · Brazil (2) · Canada (2) · Israel (2) · Netherlands (2)
Aaron Goldberg, MD (1) · Aditi Saha, M.D. (1) · Amos Burke (1) · Gwynn Long, M.D. (1) · Izidore Lossos, MD (1) · Jens Wuerthner, MD, PhD (1) · Joseph M Tuscano (1) · Juan Alderuccio, MD (1) · Juan P Alderuccio, MD (1) · Narendranath Epperla, MD (1) · Narendranath Epperla, MD, MS (1) · Narendranath Epperla, MD, MS, FACP (1) · Nitin Jain (1) · Shayna Sarosiek, MD (1)
PMID 34893942, PMID 31685491, PMID 32012214, PMID 32521310, PMID 33211842, PMID 33989558, PMID 34048682, PMID 34690090, PMID 35513980, PMID 35622074, PMID 36333463, PMID 36333464, PMID 37646659, PMID 37855688, PMID 38324336, PMID 39662486, PMID 40669032, PMID 40811783
2018 (3), 2015 (1), 2016 (1), 2017 (1), 2019 (1), P30CA093373 (1)